Future directions of liposome- and immunoliposome-based cancer therapeutics

Allen, 2004, Drug delivery systems, Science, 303, 1818, 10.1126/science.1095833

Gokhale, 1996, An improved method of encapsulation of doxorubicin in liposomes, Br J Cancer, 74, 43, 10.1038/bjc.1996.313

Batist, 2001, Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer, J Clin Oncol, 19, 1444, 10.1200/JCO.2001.19.5.1444

Gill, 1996, Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi’s sarcoma, J Clin Oncol, 14, 2353, 10.1200/JCO.1996.14.8.2353

Emerson, 2000, Antitumor efficacy, pharmacokinetics, and biodistribution of NX 211, Clin Cancer Res, 6, 2903

Sarris, 2000, Liposomal vincristine in relapsed non-Hodgkin’s lymphomas, Ann Oncol, 11, 69, 10.1023/A:1008348010437

Maeda, 2000, Tumor vascular permeability and the EPR effect in macromolecular therapeutics, J Control Release, 65, 271, 10.1016/S0168-3659(99)00248-5

Gill, 1995, Phase I/II clinical and pharmacokinetic evaluation of liposomal daunorubicin, J Clin Oncol, 13, 996, 10.1200/JCO.1995.13.4.996

Gelmon, 1999, Phase I study of liposomal vincristine, J Clin Oncol, 17, 697, 10.1200/JCO.1999.17.2.697

Hilger, 2001, Pharmacokinetics of encapsulated as well as free doxorubicin and its metabolites after intravenous infusion of Caelyx, Proc Am Soc Clin Oncol, 20, 116a

Northfelt, 1995, Pharmacokinetics and tumor localization of DOX-SL (Stealth liposomal doxorubicin) by comparison with Adriamycin in patients with AIDS and Kaposi’s sarcoma, 257

Gabizon, 1994, Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes, Cancer Res, 54, 987

Harrington, 2001, Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes, Clin Cancer Res, 7, 243

Martin, 1998, Clinical pharmacology and antitumor efficacy of DOXIL (pegylated liposomal doxorubicin), 635

Symon, 1999, Selective delivery of doxorubicin to patients with breast carcinoma metastases by stealth liposomes, Cancer, 86, 72, 10.1002/(SICI)1097-0142(19990701)86:1<72::AID-CNCR12>3.0.CO;2-1

Muggia, 1972, Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880), Cancer Chemother Rep, 56, 515

Garcia-Carbonero, 2002, Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins, Clin Cancer Res, 8, 641

Kehrer, 2002, Phase I and pharmacologic study of liposomal lurtotecan, NX 211, J Clin Oncol, 20, 1222, 10.1200/JCO.20.5.1222

Calvert, 2002, Randomized phase II trial of two intravenous schedules of the liposomal topoisomerase I inhibitor, NX211, in women with relapsed epithelial ovarian cancer (OVCA), Proc Am Soc Clin Oncol, 21, 208a

Duffaud, 2003, Phase II study of OSI-211 (formerly NX-211, liposomal lurtotecan) in patients with metastatic or loco-regional recurrent squamous cell carcinoma of the head and neck, Proc Am Soc Clin Oncol, 22, 507

Lee, 1998, Antitumor activity of 7-[2-(N-isopropylamino)ethyl]-(20S)-camptothecin, CKD602, as a potent DNA topoisomerase I inhibitor, Arch Pharm Res, 21, 581, 10.1007/BF02975379

Lee, 2000, Preclinical and phase I clinical studies with Ckd-602, a novel camptothecin derivative, Ann N Y Acad Sci, 922, 324, 10.1111/j.1749-6632.2000.tb07055.x

Folkman, 1985, Tumor angiogenesis, Adv Cancer Res, 43, 175, 10.1016/S0065-230X(08)60946-X

O’Reilly, 1994, Angiostatin, Cell, 79, 315, 10.1016/0092-8674(94)90200-3

O’Reilly, 1997, Endostatin, Cell, 88, 277, 10.1016/S0092-8674(00)81848-6

Witte, 1998, Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy, Cancer Metastasis Rev, 17, 155, 10.1023/A:1006094117427

Moulton, 1999, Angiogenesis inhibitors endostatin or TNP-470 reduce intimal neovascularization and plaque growth in apolipoprotein E-deficient mice, Circulation, 99, 1726, 10.1161/01.CIR.99.13.1726

Perrotte, 1999, Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice, Clin Cancer Res, 5, 257

Shalinsky, 1999, Broad antitumor and antiangiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials, Ann N Y Acad Sci, 878, 236, 10.1111/j.1749-6632.1999.tb07689.x

Chen, 2000, A safety and pharmacokinetic study of a mixed-backbone oligonucleotide (GEM231) targeting the type I protein kinase A by two-hour infusions in patients with refractory solid tumors, Clin Cancer Res, 6, 1259

Jansen, 2000, Chemosensitisation of malignant melanoma by BCL2 antisense therapy, Lancet, 356, 1728, 10.1016/S0140-6736(00)03207-4

Gokhale, 2002, Pharmacokinetics, toxicity, and efficacy of ends-modified raf antisense oligodeoxyribonucleotide encapsulated in a novel cationic liposome, Clin Cancer Res, 8, 3611

Dritschilo, 2003, Infusion of liposome-encapsulated c-raf antisense oligodeoxynucleotide (LErafAON) during radiation therapy in patients with advanced malignancies, Proc Am Soc Clin Oncol, 22, 224

Pei, 2004, Combination with liposome-entrapped, ends-modified raf antisense oligonucleotide (LErafAON) improves the anti-tumor efficacies of cisplatin, epirubicin, mitoxantrone, docetaxel and gemcitabine, Anticancer Drugs, 15, 243, 10.1097/00001813-200403000-00009

Shen, 2001, Liposome-C-erbB2 antisense oligodeoxynucleotides in human ovarian cancer cells, Chin Med J (Engl), 114, 735

Park, 1997, Immunoliposomes for cancer treatment, Adv Pharmacology, 40, 399, 10.1016/S1054-3589(08)60146-5

Park, 1995, Development of anti-p185HER2 immunoliposomes for cancer therapy, Proc Natl Acad Sci U S A, 92, 1327, 10.1073/pnas.92.5.1327

Kirpotin, 1997, Sterically stabilized anti-HER2 immunoliposomes, Biochemistry, 36, 66, 10.1021/bi962148u

Park, 2002, Anti-HER2 immunoliposomes, Clin Cancer Res, 8, 1172

Park, 1997, Targeted intracellular drug delivery via anti-HER2 immunoliposomes yields superior antitumor efficacy, Proc Am Soc Clin Oncol, 16, 430a

Park, 1998, Anti-HER2 immunoliposomes, Proc Am Soc Clin Oncol, 17, 216a

Marks, 1996, Phage libraries - A new route to clinically useful antibodies, N Engl J Med, 335, 730, 10.1056/NEJM199609053351008

Schier, 1995, In vitro and in vivo characterization of a human anti-c-erbB-2 single-chain Fv isolated from a filamentous phage antibody library, Immunotechnology, 1, 73, 10.1016/1380-2933(95)00007-0

Adams, 1998, Prolonged in vivo tumour retention of a human diabody targeting the extracellular domain of human HER2/neu, Br J Cancer, 77, 1405, 10.1038/bjc.1998.233

Poul, 2000, Selection of tumor-specific internalizing human antibodies from phage libraries, J Mol Biol, 301, 1149, 10.1006/jmbi.2000.4026

Becerril, 1999, Toward selection of internalizing antibodies from phage libraries, Biochem Biophys Res Commun, 255, 386, 10.1006/bbrc.1999.0177

Nielsen, 1999, Direct selection of internalizing antibodies for immunoliposome targeting of breast tumor cells, Proc Am Assoc Cancer Res, 40, 418

Nielsen, 2002, Therapeutic efficacy of anti-ErbB2 immunoliposomes targeted by a phage antibody selected for cellular endocytosis, Biochim Biophys Acta, 1591, 109, 10.1016/S0167-4889(02)00256-2

Ishida, 1999, A combinatorial approach to producing sterically stabilized (Stealth) immunoliposomal drugs, FEBS Lett, 460, 129, 10.1016/S0014-5793(99)01320-4

Kirpotin, 2000, Anti-HER2 immunoliposomes produced by spontaneous capture of an amphipathic poly(ethylene glycol)-anti-HER2 antibody conjugate into the liposome membrane, Proc Am Assoc Cancer Res, 41, 325

Iden, 2001, In vitro and in vivo comparison of immunoliposomes made by conventional coupling techniques with those made by a new post-insertion approach, Biochim Biophys Acta, 1513, 207, 10.1016/S0005-2736(01)00357-1

Park, 2001, Tumor targeting using anti-her2 immunoliposomes, J Control Release, 74, 95, 10.1016/S0168-3659(01)00315-7

Ravdin, 1999, Should HER2 status be routinely measured for all breast cancer patients?, Semin Oncol, 26, 117

Muss, 1994, c-erbB-2 expression and response to adjuvant chemotherapy in women with node-positive early breast cancer, N Engl J Med, 330, 1260, 10.1056/NEJM199405053301802

Thor, 1998, erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer, J Natl Cancer Inst, 90, 1346, 10.1093/jnci/90.18.1346

Paik, 1998, erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer, J Natl Cancer Inst, 90, 1361, 10.1093/jnci/90.18.1361

Press, 1990, Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues, Oncogene, 5, 953

Cobleigh, 1999, Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease, J Clin Oncol, 17, 2639, 10.1200/JCO.1999.17.9.2639

Slamon, 2001, Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2, N Engl J Med, 344, 783, 10.1056/NEJM200103153441101

Chien, 2000, Myocyte survival pathways and cardiomyopathy, Semin Oncol, 27, 9

Ewer, 1999, Cardiotoxicity in patients receiving trastuzumab (Herceptin), Semin Oncol, 26, 96

Park, 1992, Anti-p185HER2 monoclonal antibodies, 193

Lewis, 1993, Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies, Cancer Immunol Immunother, 37, 255, 10.1007/BF01518520

Neve, 2000, Effects of oncogenic ErbB2 on G1 cell cycle regulators in breast tumour cells, Oncogene, 19, 1647, 10.1038/sj.onc.1203470

Langer, 2004, Trastuzumab in the treatment of advanced non-small-cell lung cancer, Focus on Eastern Cooperative Oncology Group study 2598. J Clin Oncol, 22, 1180

Park, 2001, Monoclonal antibody therapy, Adv Protein Chem, 56, 369, 10.1016/S0065-3233(01)56010-6

Park, 2004, Rationale for biomarkers and surrogate end points in mechanism-driven oncology drug development, Clin Cancer Res, 10, 3885, 10.1158/1078-0432.CCR-03-0785

Mamot, 2003, Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells, Cancer Res, 63, 3154